Literature DB >> 18823215

Effect of intravenous propacetamol on blood pressure in febrile critically ill patients.

Moshe Hersch1, David Raveh, Gabriel Izbicki.   

Abstract

STUDY
OBJECTIVES: To investigate the effect of intravenous propacetamol, a parenteral bioprecursor of acetaminophen, on systemic blood pressure in critically ill patients with fever, and to establish the prevalence and clinical significance of this effect.
DESIGN: Prospective, observational study.
SETTING: A six-bed medical-surgical intensive care unit (ICU) of a university-affiliated tertiary care hospital in Israel. PATIENTS: Fourteen critically ill patients (aged 17-83 yrs) with sepsis and fever (body temperature > or = 38 degrees C) who received an intravenous infusion of propacetamol 2 g over 15-20 minutes every 6 hours as needed to reduce fever. MEASUREMENTS AND
RESULTS: Demographic data, including degree of sepsis, were collected at baseline (before propacetamol infusion). Blood pressure, heart rate, body temperature, and need for fluid or vasopressor therapy were recorded at baseline, at end of infusion, and at 15, 30, 45, 60, 90, and 120 minutes after propacetamol administration. The drug was administered on 72 occasions in the 14 patients. Mean +/- SE systolic, diastolic, and mean arterial pressures recorded 15 minutes after propacetamol administration were significantly lower than baseline measurements: 123 +/- 29 versus 148 +/- 33, 62 +/- 12 versus 70 +/- 15, and 83 +/- 16 versus 97 +/- 19 mm Hg, respectively (p<0.05). In 24 (33%) of the 72 infusions, systolic blood pressure decreased to below 90 mm Hg and required intervention with fluid bolus administration on six occasions; a fluid bolus was accompanied by a dosage increase or initiation of a norepinephrine infusion on 18 occasions. No correlation, however, was noted between the degree of decrease in mean arterial pressure and decrease in temperature (r(2)=0.01), or the degree of decrease in mean arterial pressure and decrease in heart rate (r2=0.23), at each data collection time point, as measured by linear regression.
CONCLUSION: Intravenous propacetamol, given in antipyretic doses, caused a significant decrease in blood pressure 15 minutes after administration in febrile critically ill patients. This drug-induced hypotension was clinically relevant in that interventions to control blood pressure were required. Thus, clinicians should be aware of this potential deleterious effect, particularly in specific populations such as critically ill patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18823215     DOI: 10.1592/phco.28.10.1205

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  13 in total

1.  Clinically significant hemodynamic alterations after propacetamol injection in the emergency department: prevalence and risk factors.

Authors:  June-Il Bae; Shin Ahn; Yoon-Seon Lee; Won Young Kim; Jae Ho Lee; Bum Jin Oh; Kyung Soo Lim
Journal:  Intern Emerg Med       Date:  2016-05-10       Impact factor: 3.397

2.  Haemodynamics of intravenous paracetamol in neonates.

Authors:  Karel Allegaert; Gunnar Naulaers
Journal:  Eur J Clin Pharmacol       Date:  2010-07-04       Impact factor: 2.953

3.  Paracetamol for intravenous use in medium--and intensive care patients: pharmacokinetics and tolerance.

Authors:  Monique M de Maat; Theodorus A Tijssen; Roger J Brüggemann; Huibert H Ponssen
Journal:  Eur J Clin Pharmacol       Date:  2010-03-19       Impact factor: 2.953

4.  [Paracetamol for perioperative analgesia. Old substance - new insights].

Authors:  P K Zahn; R Sabatowski; S A Schug; U M Stamer; E M Pogatzki-Zahn
Journal:  Anaesthesist       Date:  2010-10       Impact factor: 1.041

5.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

Review 6.  The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.

Authors:  Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2013-05-30       Impact factor: 4.473

Review 7.  Clinical review: fever in septic ICU patients--friend or foe?

Authors:  Yoann Launey; Nicolas Nesseler; Yannick Mallédant; Philippe Seguin
Journal:  Crit Care       Date:  2011-06-07       Impact factor: 9.097

8.  Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study.

Authors:  Byung Ho Lee; Daisuke Inui; Gee Young Suh; Jae Yeol Kim; Jae Young Kwon; Jisook Park; Keiichi Tada; Keiji Tanaka; Kenichi Ietsugu; Kenji Uehara; Kentaro Dote; Kimitaka Tajimi; Kiyoshi Morita; Koichi Matsuo; Koji Hoshino; Koji Hosokawa; Kook Hyun Lee; Kyoung Min Lee; Makoto Takatori; Masaji Nishimura; Masamitsu Sanui; Masanori Ito; Moritoki Egi; Naofumi Honda; Naoko Okayama; Nobuaki Shime; Ryosuke Tsuruta; Satoshi Nogami; Seok-Hwa Yoon; Shigeki Fujitani; Shin Ok Koh; Shinhiro Takeda; Shinsuke Saito; Sung Jin Hong; Takeshi Yamamoto; Takeshi Yokoyama; Takuhiro Yamaguchi; Tomoki Nishiyama; Toshiko Igarashi; Yasuyuki Kakihana; Younsuck Koh
Journal:  Crit Care       Date:  2012-02-28       Impact factor: 9.097

9.  Attenuation of Hemodynamic Responses to Laryngoscopy and Tracheal Intubation: Propacetamol versus Lidocaine-A Randomized Clinical Trial.

Authors:  Ali Kord Valeshabad; Omid Nabavian; Keramat Nourijelyani; Hadi Kord; Hossein Vafainejad; Reza Kord Valeshabad; Ali Reza Feili; Mehdi Rezaei; Hamed Darabi; Mohammad Koohkan; Poorya Golbinimofrad; Samira Jafari
Journal:  Anesthesiol Res Pract       Date:  2014-04-13

10.  Effect of a fever control protocol-based strategy on ventilator-associated pneumonia in severely brain-injured patients.

Authors:  Yoann Launey; Nicolas Nesseler; Audren Le Cousin; Fanny Feuillet; Ronan Garlantezec; Yannick Mallédant; Philippe Seguin
Journal:  Crit Care       Date:  2014-12-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.